Biological and Biosimilars Drug Market in Poland 2013

Biological and Biosimilars Drug Market in Poland 2013 Examine the future of biologics in the Polish pharma market. Report surveys biologic and biosimilar drugs, epidemiology and growth potential 2013- 2015. In Poland, as in many parts of the world, a growing number of patients are being treated using biological or biosimilar drugs. The list of illnesses for which these drugs are prescribed includes psoriasis, Crohns disease, colitis, psoriatic and rheumatoid arthritis, ankylosing spondylitis and others. Consequently, the market has expanded recently to encompass new drugs and therapies designed to treat a growing variety of conditions and illnesses. Biologic and biosimilars drug market in Poland 2013, Development forecasts for 2013-2015 is a new PMR report designed to evaluate current market conditions and investigate the possibilities for growth and expansion in the coming years. From market size to research and development efforts of leading companies, this publication offers expert analysis of this market. This document analyses the epidemiology fueling the growth of biologics in Poland, revealing the number of patients receiving these drugs. It analyses the reasons behind expansion and the potential obstacles that exist or will appear by 2015. The competitive atmosphere of this segment of Polands pharmaceuticals market is carefully evaluated using profiles of the major Polish manufacturing companies active in this market that include financial condition updates, plans for upcoming additions to their product lines and plans to engage in new research and development activities. Recent entries into the Polish biologics market are examined along with the likelihood of M&A and consolidation activity in the next two years.

Biological and Biosimilars Drug Market in Poland 2013

The expiration of various patents for biologic drugs is a timely market topic, and this publication highlights the businesses ready to capitalise on new developments. It reviews the...